NCT05142293 (OEDIPE-CRT-P) is a clinical trial of Ambulatory procedure in Heart Failure, sponsored by Biotronik SE & Co. KG.

Who is sponsoring NCT05142293?

NCT05142293 is sponsored by Biotronik SE & Co. KG.

What drugs are being tested in NCT05142293?

Interventions in NCT05142293: Ambulatory procedure.

What condition does NCT05142293 study?

NCT05142293 studies Heart Failure.

Is NCT05142293 still recruiting?

NCT05142293 is currently active, enrolled. Last updated 26 December 2025.

Last reviewed 2025-12-26 · How we verify

NCT05142293: OEDIPE-CRT-P

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

One Day Implantation Program for Heart Failure Patients Implanted With CRT-P

Active, enrolled Last updated 26 December 2025

What this trial tests

trial testing Ambulatory procedure in Heart Failure in 354 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 December 2021

Primary endpoint
31 January 2026

31 May 2026

Quick facts

Lead sponsor	Biotronik SE & Co. KG
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	354
Start date	6 December 2021
Primary completion	31 January 2026
Estimated completion	31 May 2026
Sites	19 locations across France

Drugs / interventions tested

Ambulatory procedure

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Biotronik SE & Co. KG — full company profile →

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study has been implemented to evaluate cardiac resynchronization therapy pacemaker (CRT-P) implantations on a same-day basis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Biotronik SE & Co. KG trials

Trials by the same sponsor.

NCT07393009 — Studying Routine Patient Care With BIOTRONIK Devices That Allow a More Natural Heart Stimulation · not yet recruiting
NCT06989580 — BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specif · NA · recruiting
NCT06018818 — Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family · NA · completed
NCT05426785 — To Evaluate the Delivery Timing Safety and Efficacy of AntiTachycardia Pacing (BIO|ATP) · NA · recruiting
NCT05761249 — BIOSTREAM.HF HeartInsight · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05142293 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biotronik SE & Co. KG
Last refreshed: 26 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05142293.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing